Production Way, Burnaby, B.C., V5A 4R4
(604) 551-7831 Fax:
Notice of Allowance for Detection
of Molecules -
give law enforcement and employers
Columbia -- May
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC PINK: BLOZF) (the
of the Cannabix Marijuana Breathalyzer devices
enforcement and the workplace, reports that it has received a notice of
United States Patent and
Trademark Office (USPTO) for patent
application, No. 17/019728
"Apparatus and Methods
for Detection of Molecules".
Track 1 patent application is centered on
Cannabix with its
asymmetric waveform ion mobility spectrometry)
breathalyzer technology. This patent application is the culmination
of research and development work conducted by Cannabix scientists
and engineers in the areas of ion mobility spectrometry,
non-volatile molecule sampling and fluid
utility in several
related to detection of molecules in breath.
Cannabix is using its
FAIMS technology to isolate and detect ?9-tetrahydrocannabinol
a non-volatile compound, in breath. The Cannabix FAIMS marijuana
breathalyzer device uses ion mobility filtering techniques (related
to mass spectrometry – the gold standard analytical technique for
molecular detection). The Cannabix device
has been designed and built in a series of modules that together
allow for sample intake, ionization, filtering and detection – all
done under atmospheric pressure. In addition, the
device has the ability to couple directly
to a mass spectrometer
in order to validate its detector responses.
It should be noted
that a notice
of allowance from the USPTO does
not constitute a grant of patent. The Company will report on
future material developments regarding its "Apparatus and Methods
for Detection of Molecules" patent application
in due course.
The Company has
its intellectual property (IP)
recent months. In
April, the Company
of allowance for its
application, No. 2887841 entitled, "Cannabis Drug Detection Device"
Intellectual Property Office (CIPO). In addition,
Company was granted a granted patent No.
14/689434 entitled, "Cannabis Drug Detection Device"
USPTO in January 2021. The newly received
USPTO for its FAIMS related
patent application builds on this IP momentum.
The Company expects
to ship its THCBA to a clinic in
U.S. for beta
testing in May.
collaborating clinic has a robust drug testing operation and is one
of the top drug testing providers to employers within its respective
testing is focussed
experience through testing and
the device's machine learning database.
Inc. is a developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law
enforcement to identify
recent marijuana use that better
aligns with impairment.
We seek Safe
behalf of the Board of Directors
further information, contact the Company at
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.